NYNRIN safeguards leukemia stem cells by sustaining thioredoxin activity to maintain redox homeostasis
In patients with acute myeloid leukaemia (AML), the presence of leukaemic stem cells (LSCs) promotes resistance to therapy and is associated with poor prognosis.